AI Article Synopsis
- Dasatinib is a second-generation tyrosine kinase inhibitor recommended as the first-line treatment for newly diagnosed chronic myeloid leukemia (CML) and as a second-line option for patients resistant to imatinib.
- It shows better clinical response compared to imatinib but is associated with serious pulmonary side effects like pulmonary arterial hypertension and pleural effusion.
- Effective management of these adverse reactions is crucial for enhancing patient quality of life and prognosis in CML treatment.
Article Abstract
Dasatinib, a second-generation tyrosine kinase inhibitor, is recommended as first-line treatment for patients newly diagnosed with chronic myeloid leukemia (CML) and second-line treatment for those who are resistant or intolerant to therapy with imatinib. Dasatinib is superior to imatinib in terms of clinical response; however, the potential pulmonary toxicities associated with dasatinib, such as pulmonary arterial hypertension and pleural effusion, may limit its clinical use. Appropriate management of dasatinib-related severe events is important for improving the quality of life and prognosis of patients with CML. This review summarizes current knowledge regarding the characteristics, potential mechanisms, and clinical management of adverse reactions occurring after treatment of CML with dasatinib.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939513 | PMC |
| http://dx.doi.org/10.3389/fonc.2023.1113462 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!